CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avicena Group, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avicena Group, Inc.
228 Hamilton Ave
3rd floor
Phone: (415) 397-2880p:415 397-2880 Palo Alto, CA  94301  United States Ticker: AVCEAVCE

This company is no longer actively traded on any major stock exchange.

Business Summary
Avicena Group, Inc. is a biotechnology and nutraceutical company, which is focused to develop and commercialize distinctive drug, cosmetic and nutritional products that deliver value by improving the lives of patients by regulating critical energy processes, which occur within cells. As of December 31, 2007, it was licensing cosmeceutical products and selling a nutraceutical product. As of December 31, 2007, none of its drug candidates were approved for commercial sale. As of December 31, 2007, it had five products in clinical trials, of which two products are in Phase III trials, two products are in Phase II trials and one product in Phase I trials. The Company’s research is focused on those biochemicals that influence the body’s ability to modulate cellular energy production via the creatine kinase (CK) system and cellular energy transport via the creatine transporter (CT) system.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200812/31/2007YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Belinda T.Nivaggioli 40 10/1/2007 1/1/1999
Acting Chief Financial Officer, Vice President - Finance Michael J.Sullivan 54 3/1/2003
Vice President - Marketing & Business Strategy BolkoZu Stolberg 49 11/1/2004 11/1/2004
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AVCE
AVGO
Avicena Group Inc.
Avicena Group, Inc.

General Information
Number of Employees: 3 (As of 12/31/2007)
Outstanding Shares: 50,748,453 (As of 4/30/2008)
Shareholders: 305
Stock Exchange: OTC
Federal Tax Id: 043195737
Fax Number: (415) 397-2898
Email Address: info@avicenagroup.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023